Myriad Genetics names Vishal Sikri as EVP of Commercial, effective September 16, 2026

Myriad Genetics, Inc. (NASDAQ: MYGN) announced on September 16, 2026 that Vishal Sikri has been named Executive Vice President - Commercial, effective that same day. The company describes itself as a leader in molecular diagnostic testing and precision medicine.¹

According to the company's Form 8-K, the board of directors made the appointment on September 15, 2026, moving Sikri from his prior role as the company's Senior Vice President, Product, into the new commercial leadership post. Sikri had held the SVP of Product title at Myriad for the year before his promotion.¹ The company said he brings deep knowledge of molecular diagnostics and oncology along with business and commercial leadership experience from earlier roles at other companies.¹

The move follows the exit of Brian Donnelly, who had been Chief Commercial Officer since May 2025. Donnelly will leave Myriad on September 21, 2026.¹ Per the filing, he stops serving as an executive officer on September 16, 2026, but stays on in a non-executive capacity for a few more days to help hand off his duties.

CEO Sam Raha commented on the transition, thanking Donnelly and expressing confidence in Sikri's new role. Raha said the company is excited to have Sikri lead the commercial organization, citing his domain knowledge and track record as important to executing the company's cancer care continuum strategy and growth plans.¹ Sikri said he is energized to lead the commercial team and looks forward to working with Raha and the leadership team to serve more patients and providers.¹

Alongside the leadership announcement, Myriad confirmed its full-year 2026 financial outlook remains unchanged from the figures it gave on its second-quarter 2026 earnings call, held July 30, 2026.